Результаты поиска

A Cost-Effectiveness Analysis of the Sentio Bone Conduction Hearing Implant System in the Australian Healthcare Setting.

Bone conduction hearing implant systems (BCHIs) are established treatments for patients with conductive or mixed hearing loss or single-sided deafness when conventional hearing aids are unsuitable. This study evaluated the cost-effectiveness of the active transcutaneous system Sentio versus a similar system, i.e., Osia in an Australian setting. Scenario analyses also compared Sentio to other systems, i.e., Ponto and Baha Attract. A Markov cohort model was adapted from a previously published source to reflect Australian practice, incorporating device acquisition, surgery, maintenance, battery r

Cost-Effectiveness of Cilta-cel in Lenalidomide-Refractory Multiple Myeloma: An Analysis of the CARTITUDE-4 Trial.

OBJECTIVE: Building upon the survival advantages demonstrated in the Phase III CARTITUDE-4 trial, this study quantifies the cost-effectiveness of ciltacabtagene autoleucel (cilta-cel) versus standard regimens (PVd or DPd) for lenalidomide-refractory multiple myeloma from a US mixed payer perspective. METHODS: A Markov model with 3 or 4-week cycles was developed to simulate long-term clinical trajectories. The economic viability was determined by calculating incremental cost-effectiveness ratios (ICERs) through integrated costs and quality-adjusted life years (QALYs), benchmarked against a will

Long-Acting PrEP for People With High Vulnerability to HIV Acquisition in Brazil: A Cost-Effectiveness Analysis.

INTRODUCTION: In Brazil, men who have sex with men (MSM) and transgender women (TGW) remain heavily affected by HIV. Long-acting pre-exposure prophylaxis (LA PrEP) with injectable cabotegravir (CAB-LA) or lenacapavir (LEN-LA) is more effective at preventing HIV acquisition than oral PrEP. Our objective was to assess the potential clinical and economic impact of offering CAB-LA or LEN-LA to MSM and TGW with high vulnerability to HIV acquisition in Brazil and determine the maximum cost at which they would be cost-effective. METHODS: We used the CEPAC microsimulation model of HIV prevention and

Lymph node assessment at the time of robotic hysterectomy for endometrial intraepithelial neoplasia: A cost-effectiveness analysis.

OBJECTIVE: We sought to determine the cost-effectiveness (CE) of lymph node dissection (LND) at the time of hysterectomy for endometrial intraepithelial neoplasia (EIN). METHODS: A decision analytic model was created to evaluate the strategies of routine full LND, sentinel lymph node dissection (SNLD), SNLD without advancing to full LND in the event of non-mapping, and full LND based on Mayo Criteria, versus no LND. Patients in the no LND group and those in the SLND group without advancement to full LND in the event of non-mapping who were found to have EC on final pathology and suspicious po

Cost-effectiveness analysis of deep brain stimulation versus treatment as usual for treatment-resistant obsessive-compulsive disorder.

OBJECTIVE: Deep brain stimulation (DBS) is an effective neurosurgical option for patients with treatment-resistant obsessive-compulsive disorder (OCD). Despite being more costly than neuroablative procedures of comparable efficacy, DBS has gained popularity over the years for its reversibility and adjustability. Although the cost-effectiveness of DBS has been investigated extensively in movement disorders, few economic analyses of DBS for psychiatric disorders exist. In this study, the authors present the first cost-effectiveness analysis of DBS for treatment-resistant OCD in the United States…

Dihydropyrimidine Dehydrogenase Deficiency (DPYD) Genotyping-Guided Fluoropyrimidine-Based Adjuvant Chemotherapy for Breast Cancer. A Cost-Effectiveness Analysis.

BACKGROUND AND OBJECTIVE: While standard doses of adjuvant fluoropyrimidine-based chemotherapies are generally safe for most patients, the risk of severe adverse drug reactions (ADRs) is increased for those with dihydropyrimidine dehydrogenase deficiency (DPYD), a genetic variation that affects drug metabolism. The objective of this study was to examine the cost effectiveness of offering DPYD pharmacogenetic-guided care, where genetic testing informs personalized dosing versus the current standard of care (SoC), which involves administering fluoropyrimidine-based therapies without prior geneti

Cervical cancer screening by cotesting method for Vietnamese women 25-55 years old: a cost-effectiveness analysis.

BACKGROUND: Cervical cancer (CC) is preventable through regular screening and vaccination against human papillomavirus (HPV). However, CC re … ). The objective is to provide evidence to inform policy and clinical practice in Vietnam. DESIGN: Cost-effectiveness analysis using a Markov model with 1 year cycles to simulate the natural progression of CC. SETTING: The Vietnamese healthcare system, modelled from the provider's perspective, with parameters adapted to the local context through expert consultations. PART …

Cost-effectiveness analysis of perioperative durvalumab plus platin-based chemotherapy in muscle invasive bladder cancer in Germany.

BACKGROUND: The NIAGARA trial evaluated the efficacy of adding perioperative immunotherapy with durvalumab to standard gemcitabine/cisplatin chemotherapy in muscle-invasive bladder cancer (MIBC). In light of the rising financial burden associated with the treatment of urothelial carcinoma and the favorable clinical outcomes reported in the NIAGARA trial, we conducted a cost-effectiveness analysis based on clinical data to determine whether the inclusion of durvalumab is also justified from a socioeconomic standpoint in Germany. METHODS: We constructed a Markov model from the payer's perspecti…

Cost-effectiveness analysis of ropeginterferon alfa-2b for the management of patients with polycythemia vera in Japan.

OBJECTIVE: To verify the clinical benefit of ropeginterferon alfa-2b (ropegIFN) and evaluate its cost-effectiveness compared with hydroxycarbamide or ruxolitinib for patients with polycythemia vera (PV) under the National Health Insurance (NHI) system in Japan. METHODS: The cost-effectiveness of ropegIFN compared with hydroxycarbamide or ruxolitinib was evaluated for patients with PV requiring cytoreductive therapy (without prior cytoreductive therapy) and resistant or intolerant to hydroxycarbamide. According to previous reports, patients with PV who achieve a molecular response with a JAK2V

Cost-effectiveness analysis of second intravenous immunoglobulin infusion versus infliximab for treating IVIG-resistant Kawasaki disease patients.

OBJECTIVE: Intravenous immunoglobulin (IVIG) is a known effective treatment to reduce the incidence of coronary artery aneurysms in Kawasaki disease (KD) patients. However, there has been an increase in IVIG-resistant patients and a lack of clinical trial data to determine the best second treatment. The Kawasaki Disease Comparative Effectiveness (KIDCARE) trial was a randomized trial comparing infliximab to a second IVIG infusion. Data from the trial were used for a cost-effectiveness analysis. METHODS: We developed a decision tree to estimate total costs and outcomes and calculated cost-effec…

Impella Versus VA-ECMO for Patients with Cardiogenic Shock: Preliminary Cost-Effectiveness Analysis in the Italian Context.

INTRODUCTION: Cardiogenic shock (CS) is a life-threatening failure of the heart to supply adequate blood, requiring immediate treatment. Although nowadays Impella® heart pumps and veno-arterial extra-corporeal membrane oxygenation (VA-ECMO) are both widely employed in routine clinical practice for the management of patients with CS, extensive comparative information on their cost-effectiveness is lacking. The aim of the present study was to conduct a cost-effectiveness analysis comparing Impella to VA-ECMO in patients with CS from the National Healthcare Service (NHS) perspective in Italy. A s…

Cost-effectiveness of population-based expanded reproductive carrier screening for genetic diseases in Australia: a microsimulation analysis.

Using the Australian Census survey 2021 as base population, a microsimulation model, PreconMOD was developed to evaluate the cost-effectiveness of population-based expanded reproductive carrier screening (RCS) for 569 recessive conditions from the health service and societal perspectives. The model simulated the effect of expanded RCS including the downstream interventions for at-risk couples on cost and outcomes. The comparators were (i) no population screening (ii) limited screening for cystic fibrosis, spinal muscular atrophy, and fragile X syndrome and (iii) a 300 conditions screening pane

Cost-effectiveness analysis of AI-assisted chest X-ray interpretation tools for TB screening: a rapid HTA.

BACKGROUND: Early diagnosis remains one of the major barriers to treating and managing tuberculosis (TB). Artificial intelligence (AI) has i … with the conventional method, i.e., manual interpretation by radiologists using digital X-rays. The cost-effectiveness analysis was undertaken using the Health Technology Assessment in India (HTAIn) guidelines. The incremental cost per additional interpreted case was the outcome. FINDINGS: The incremental cost-effectiveness ratio (ICER) for qXR was Indian rupee (INR) -9,865 …

Cost-effectiveness analysis of romosozumab for severe postmenopausal osteoporosis at very high risk of fracture in Mexico.

INTRODUCTION: This study aims to assess the cost effectiveness of romosozumab versus teriparatide, both sequenced to denosumab, for the treatment of severe postmenopausal osteoporosis at very high risk of fractures in Mexican women. METHODS: A Markov model was used to assess the relative cost effectiveness of 1 year of romosozumab versus 2 years of teriparatide, both sequenced to denosumab for a total treatment duration of 5 years. Outcomes for a cohort of women with a mean age of 74 years, a T-score ≤-2.5 and a previous fragility fracture were simulated over a lifetime horizon. The analysis

Placental Allograft Reconstruction of Cutaneous Wounds Following Mohs Surgery: A Propensity Score-Matched Comparative Cost-Effectiveness Analysis.

BACKGROUND: The purpose of this study was to examine the cost-effectiveness of placental allograft as a nonoperative surrogate to autologous tissue-based methods of defect reconstruction on the face, head, and dorsal hand following Mohs micrographic surgery (MMS). METHODS: This study was a 5-year retrospective, analysis comparing propensity-matched cohorts of eligible Mohs surgery patients treated with a placental allograft (dHACM, dehydrated human amnion/chorion membrane) vs autologous tissue-based repairs. Costs on day 0 through discharge were used for a cost-effectiveness analysis (CEA) an…

Optimizing vitamin A supplementation: A comparative cost-effectiveness analysis of routine distribution strategies in northern Côte d'Ivoire.

BACKGROUND: While recent data on vitamin A deficiency (VAD) prevalence is lacking, the 2004 Côte d'Ivoire Nutrition and Mortality Survey rep … ssessed through a post-event coverage survey (PECS) via a two-stage cluster sampling methodology. A cost-effectiveness analysis determined the cost per child supplemented, the cost per DALY averted, and a sensitivity analysis tested the robustness of the findings under different cost scenarios. RESULTS: The total program cost for July-December 2023 was 25.5 million FCFA, wi …

The cost-effectiveness analysis of single-tablet efavirenz-based regimen among HIV-1 infected adults in China.

INTRODUCTION: In 2018, the Chinese Guidelines for Diagnosis and Treatment of HIV/AIDS recommended the adoption of the efavirenz 400 mg-based TLE (tenofovir disoproxil fumarate (TDF) + lamivudine (3TC) + efavirenz (EFV)) regimen as the primary first-line treatment for ART-naive HIV-1 infected adults in China. However, the cost-effectiveness of different TLE treatment strategies remains uncertain. This study aimed to evaluate the cost-effectiveness of various TLE treatment strategies for ART-naive HIV-1 infected adults in China. METHODS: A decision-tree Markov state transition model was employe

Анализ эффективности затрат, связанных с офатумумабом и терифлюномидом, для повторного выброса нескольких склерозов: A 10-Year Марковская модель.

СПРАВОЧНАЯ ИНФОРМАЦИЯ И ЦЕЛИ: Офатумумаб, полностью человек anti-CD20 Моноклональная антитела является перспективной терапией для изменения заболеваний (DMT) для повторного излучаемого многократного склероза (RRMS). В этом исследовании анализируется его рентабельность по сравнению с терифлюномидом с точки зрения саудовских работников здравоохранения. Это сопоставление имеет важнейшее значение для разработки стратегий лечения и распределения ресурсов в Саудовской Аравии, где ОСРЗ создает значительную нагрузку на здравоохранение и эволюционирует доступ к новым ДМТ. ПАТИЕНТЫ И МЕТОДЫ: Марковская

Совпадение в аннотации оригинала
BACKGROUND AND OBJECTIVES: Ofatumumab, a fully human anti-CD20 monoclonal antibody, is a promising disease-modifying therapy (DMT) for relap … a 99.14% probability of cost-effectiveness in probabilistic sensitivity analyses. CONCLUSION: This cost-effectiveness analysis demonstrates that ofatumumab is a cost-effective treatment for RRMS in Saudi Arabia, with an ICER below the WTP. Policymakers should consider including ofatumumab in national formularies and prioritize its use in early-stage RRMS to maximize patient …

Intended Conservative Management Versus Caesarean Hysterectomy for Known or Suspected Placenta Accreta Spectrum: A Cost-Effectiveness Analysis.

OBJECTIVE: We examined the cost-effectiveness of conservative management (CM) compared to planned caesarean hysterectomy (CH) for placenta accreta spectrum (PAS). DESIGN: A cost-effectiveness analysis in a theoretical cohort of patients. SETTING: A decision analytic model. POPULATION: A theoretical cohort of 1000 pregnant patients with PAS greater than 20 weeks gestation. METHODS: In base case analysis, we assumed that between 20% and 40% of individuals would be eligible for CM. Model inputs were derived from the literature. Analysis was conducted from a healthcare system perspective with …

Cost-effectiveness analysis of the 20-valent pneumococcal conjugate vaccine for the pediatric population in South Korea.

OBJECTIVES: To evaluate the cost-effectiveness of the 20-valent pneumococcal conjugate vaccine (PCV20) compared to 13-valent pneumococcal conjugate vaccine (PCV13) for the pediatric population in Korea, where the four-dose vaccine coverage rate is over 97%. METHODS: We constructed a Markov model to calculate the cost and quality-adjusted life-years (QALYs) over 10 years. The health states were susceptible states; disease states, which included invasive pneumococcal diseases such as meningitis, bacteremia, pneumonia, and acute otitis media; and death attributable to pneumococcal disease. The a